Sarah’s practice focuses on a broad range of corporate transactions, including mergers and acquisitions, venture financings, licensing/commercial technology transactions, and everyday corporate strategy and governance matters. She represents private companies throughout their life cycles, from company formation up and until they go public or engage in a sale of the company, often serving as outside general corporate counsel. Sarah’s practice spans across multiple industries, primarily technology, life sciences, and financial services. Her experience includes representing both companies and investors in a wide range of financing transactions, including convertible note and Simple Agreement for Future Equity (SAFE) offerings. Sarah also represents family offices and funds in the acquisition of and investment in other businesses.
Sarah regularly guest lectures to entrepreneurs and start-ups on the topics of entity formation and early-stage financings at MIT’s Sloan School of Management.
Before joining Mintz, Sarah was an associate and summer associate in the Boston office of a global law firm, where she worked with public and private companies on general corporate and transactional matters.
During law school, Sarah served as a legal intern at Social Finance, Inc., a nonprofit that mobilizes private capital to create innovative financing programs designed to provide social benefits to communities all over the world. She also worked in the Boston office of a global custodian bank as a proxy voting & governance analyst, and spent time at the Federal Reserve Bank of Boston as a legal intern.
Prior to attending law school, Sarah was a Teach For America Corps Member and spent three years as a middle school teacher in Baltimore.
- Represented pharmaceutical company in a reverse merger IPO valued at up to $500 million.
- Represented telehealth company in its acquisition of another digital health company for aggregate value of $138 million.
- Represented tactical equipment manufacturer in the sale of one of its business lines to a private investment firm for aggregate value of up to $97.5 million.
- Represented tech gadget manufacturer in its acquisition by a strategic buyer for an aggregate value of up to $70 million.
- Represented a family office in the acquisition of an autism services company for an aggregate value of up to $15 million.
- Represented a medical device company in a $400,000 “friends and family” convertible note financing.
- Represented pharmaceutical company in a three-tranche Series A financing valued at up to $45 million.
- Represented a life science company in its $90 million Series D financing.
- Represented German VC fund in its investment in a $35 million Series B financing.
- Represented European enterprise software company in a corporate reorganization and cross-border $20 million Series A financing.
- Represented drug development company in its $150 million Series A financing.
- Represented insurtech company in its $3 million Series Seed financing.
- Regularly represent technology-focused strategic investor in international early- to mid-stage venture financings.
- Regularly represent fund-incubated life science companies.
- Represent start-up companies on formation and corporate structure, including drafting stockholders and founders agreements; form of equity incentive plans and stock option agreements; nondisclosure, non-competition and invention assignment agreements; stock restriction and stock purchase agreements; and the filing of 83(b) elections.
- Represent education non-profit in ongoing IP licensing and commercial contract needs.
- Represent SaaS company in negotiation of terms of service and commercial contracts with customers.
News & Press
October 15, 2020
- Member, Boston Bar Association
- Member, Massachusetts Bar Association
- Greater Boston Chamber of Commerce